Camurus
589.00 SEK
-0.93 %
Less than 1K followers
CAMX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-0.93 %
-8.47 %
-15.13 %
-2.32 %
+4.16 %
+4.62 %
+121.43 %
+215.31 %
+874.75 %
Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.
Read moreMarket cap
35.27B SEK
Turnover
185.41M SEK
Revenue
1.87B
EBIT %
25.12 %
P/E
79.7
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12/2
2026
Annual report '25
12/5
2026
Interim report Q1'26
28/5
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
Camurus AB: Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism
Camurus AB: Change in number of shares and votes in Camurus
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
